{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T07:31:30Z","timestamp":1771486290937,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","annemergmed.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Emergency Medicine"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.annemergmed.2016.08.008","type":"journal-article","created":{"date-parts":[[2016,11,5]],"date-time":"2016-11-05T00:16:17Z","timestamp":1478304977000},"page":"327-336.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department"],"prefix":"10.1016","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-8826","authenticated-orcid":false,"given":"Jon B.","family":"Cole","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna C.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin J.","family":"Dolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"O\u2019Brien-Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brandon J.","family":"Fryza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James R.","family":"Miner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc L.","family":"Martel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.annemergmed.2016.08.008_bib1","series-title":"Goldfrank\u2019s Toxicologic Emergencies","first-page":"960","article-title":"Antipsychotics","author":"Juurlink","year":"2015"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib2","unstructured":"Eli Lilly and Company. Olanzapine [package insert]. Available at: http:\/\/pi.lilly.com\/us\/zyprexa-pi.pdf. Accessed May 15,\u00a02016."},{"key":"10.1016\/j.annemergmed.2016.08.008_bib3","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/S0149-2918(03)80129-7","article-title":"A\u00a0comparison of the efficacy and\u00a0safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy","volume":"25","author":"Wright","year":"2003","journal-title":"Clin Ther"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/acem.12842","article-title":"A\u00a0large retrospective cohort of patients receiving intravenous olanzapine in the emergency department","volume":"23","author":"Martel","year":"2016","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib5","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.1553-2712.2008.00197.x","article-title":"Olanzapine versus droperidol for the treatment of primary headache in the emergency department","volume":"15","author":"Hill","year":"2008","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib6","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1111\/j.1553-2712.2005.tb01492.x","article-title":"Management of acute undifferentiated agitation in the emergency department: a randomized double-blind trial of droperidol, ziprasidone, and midazolam","volume":"12","author":"Martel","year":"2005","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib7","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jemermed.2010.07.005","article-title":"Droperidol analgesia for opioid-tolerant patients","volume":"41","author":"Richards","year":"2011","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib8","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/PEC.0b013e3181d6d9f2","article-title":"Droperidol use in pediatric emergency department patients","volume":"26","author":"Szwak","year":"2010","journal-title":"Pediatr Emerg Care"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib9","unstructured":"American Society of Hospital System Pharmacists. Current drug shortage bulletin: droperidol injection. Available at: http:\/\/www.ashp.org\/menu\/DrugShortages\/CurrentShortages\/Bulletin.aspx?id=818. Accessed May 15,\u00a02016."},{"key":"10.1016\/j.annemergmed.2016.08.008_bib10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1080\/10903120590891723","article-title":"Discontinuation of droperidol for the control of acutely agitated out-of-hospital patients","volume":"9","author":"Martel","year":"2005","journal-title":"Prehosp Emerg Care"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib11","unstructured":"Novartis Pharmaceuticals Corporation. Metoprolol tartrate. Available at: https:\/\/www.pharma.us.novartis.com\/product\/pi\/...\/lopressor.pdf. Accessed May 15,\u00a02016."},{"key":"10.1016\/j.annemergmed.2016.08.008_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.annemergmed.2012.07.118","article-title":"Intravenous droperidol or olanzapine as an adjunct to midazolam for the acutely agitated patient: a multicenter, randomized, double-blind, placebo-controlled clinical trial","volume":"61","author":"Chan","year":"2013","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib13","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1111\/j.1553-2712.2002.tb01609.x","article-title":"A\u00a0retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population","volume":"9","author":"Chase","year":"2002","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib14","unstructured":"Code of Federal Regulations. Title 45, part 46.116(d). General requirements for informed consent. 2009."},{"key":"10.1016\/j.annemergmed.2016.08.008_bib15","unstructured":"Code of Federal Regulations. Title 21, Part 50.24. Guidance for institutional review boards, clinical investigators, and sponsors: exception from informed consent requirements for emergency research. 2011."},{"key":"10.1016\/j.annemergmed.2016.08.008_bib16","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.annemergmed.2014.08.046","article-title":"Randomized, double-blinded, clinical trial of propofol, 1:1 propofol\/ketamine, and 4:1 propofol\/ketamine for deep procedural sedation in the emergency department","volume":"65","author":"Miner","year":"2015","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib17","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1553-2712.2001.tb01147.x","article-title":"Droperidol vs. prochlorperazine for benign headaches in the emergency department","volume":"8","author":"Miner","year":"2001","journal-title":"Acad Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jemermed.2003.05.005","article-title":"Droperidol vs prochlorperazine for the treatment of acute headache","volume":"26","author":"Weaver","year":"2004","journal-title":"J\u00a0Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib19","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.annemergmed.2015.03.016","article-title":"The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department","volume":"66","author":"Calver","year":"2015","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib20","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/j.ajem.2012.03.013","article-title":"Olanzapine in ED patients: differential effects on oxygenation in patients with alcohol intoxication","volume":"30","author":"Wilson","year":"2012","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/alcalc\/ags035","article-title":"Emergency department visits due to alcohol intoxication: characteristics of patients and\u00a0impact on the emergency room","volume":"47","author":"Verelst","year":"2012","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib22","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A\u00a0randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib23","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/JCP.0000000000000142","article-title":"Lack of effect of risperidone or olanzapine dose reduction on metabolic parameters, prolactin, and corrected QT interval in stable patients with schizophrenia","volume":"34","author":"Takeuchi","year":"2014","journal-title":"J\u00a0Clin Psychopharmacol"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2190\/U99G-XDML-0GRG-BYE0","article-title":"Severe cardiovascular side effects of olanzapine in an elderly patient: case report","volume":"33","author":"Lee","year":"2003","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/0091270002042001013","article-title":"Hypotension and bradycardia in a healthy volunteer following a single 5 mg dose of olanzapine","volume":"42","author":"Markowitz","year":"2002","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib26","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/YIC.0b013e32805aedf5","article-title":"Olanzapine overdose: a series of analytically confirmed cases","volume":"22","author":"Morgan","year":"2007","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib27","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1007\/s00520-012-1710-6","article-title":"The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy","volume":"21","author":"Navari","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.annemergmed.2016.08.008_bib28","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.suponc.2011.05.002","article-title":"Olanzapine versus aprepitant for the prevention of chemotherapy induced nausea and vomiting: a randomized phase III trial","volume":"9","author":"Navari","year":"2011","journal-title":"J\u00a0Support Oncol"}],"container-title":["Annals of Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064416304668?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0196064416304668?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,6]],"date-time":"2018-09-06T19:55:19Z","timestamp":1536263719000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0196064416304668"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0196064416304668"],"URL":"https:\/\/doi.org\/10.1016\/j.annemergmed.2016.08.008","relation":{},"ISSN":["0196-0644"],"issn-type":[{"value":"0196-0644","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Prospective Observational Study of Patients Receiving Intravenous and Intramuscular Olanzapine in the Emergency Department","name":"articletitle","label":"Article Title"},{"value":"Annals of Emergency Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2016.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.annemergmed.2016.09.021","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 by the American College of Emergency Physicians.","name":"copyright","label":"Copyright"}]}}